Difference between revisions of "Main Page"
Warner-admin (talk | contribs) m (Text replacement - "Autologous HSCT" to "Autologous HSCT conditioning regimens") |
Warner-admin (talk | contribs) |
||
(13 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
</div> | </div> | ||
− | <div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology | + | <div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div> |
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | ||
|- | |- | ||
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,087 |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd" | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:#3c0008;">Guidelines: 1,217</span> |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6, | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,665 |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7, | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,589 |
|- | |- | ||
|} | |} | ||
Line 334: | Line 334: | ||
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] | |colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] | ||
|- | |- | ||
− | |colspan="4" style="font-size:125%; background-color:#fc9272"|''' | + | |colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders''' |
|- | |- | ||
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | |style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | ||
Line 391: | Line 391: | ||
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | |style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | ||
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]] | |style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]] | ||
− | |style="width: 25%; background-color:#efedf5"|[[Autologous HSCT | + | |style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]] |
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]] | |style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]] | ||
|- | |- | ||
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]] | |style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]] | ||
− | |style="background-color:#efedf5"| | + | |style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]] |
|style="background-color:#efedf5"| | |style="background-color:#efedf5"| | ||
|style="background-color:#efedf5"| | |style="background-color:#efedf5"| | ||
Line 410: | Line 410: | ||
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]] | |style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | |style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | ||
+ | |style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]] | ||
+ | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | ||
− | |||
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]] | |style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]] | ||
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]] | |style="background-color:#e5f5e0"|[[Inherited thrombophilia]] | ||
+ | |- | ||
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]] | |style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]] | ||
− | |||
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]] | |style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]] | ||
− | |||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
Line 434: | Line 434: | ||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
|- | |- | ||
− | |colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders''' | + | |colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies''' |
|- | |- | ||
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | |style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | ||
Line 441: | Line 441: | ||
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | |style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | ||
|- | |- | ||
− | | | + | |style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]] |
− | | | + | |style="background-color:#e5f5e0"|[[Beta thalassemia]] |
− | | | + | |style="background-color:#e5f5e0"|[[Sickle cell anemia]] |
− | | | + | |style="background-color:#e5f5e0"| |
|- | |- | ||
|} | |} | ||
Line 456: | Line 456: | ||
Priorities of this project include: | Priorities of this project include: | ||
+ | <section begin=goals /> | ||
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]]. | *'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]]. | ||
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles). | *'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles). | ||
Line 461: | Line 462: | ||
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources. | *'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources. | ||
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens. | *'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens. | ||
+ | <section end=goals /> | ||
Additional possibilities for this project may include: | Additional possibilities for this project may include: |
Revision as of 12:20, 1 June 2024
HemOnc.org - A Free Hematology/Oncology Reference
Regimens: 5,087 | Guidelines: 1,217 | Studies: 6,665 | References: 7,589 |
---|
Solid Tumors | Malignant Hematology | Pediatrics | Transplant & IEC | Classical Hematology |
Links to all main disease pages
Pediatric Neoplasms | |||
---|---|---|---|
Pediatric CNS malignancies | |||
Low-grade glioma | High-grade glioma | Medulloblastoma | |
Pediatric hematologic neoplasms | |||
B-cell acute lymphoblastic leukemia (B-ALL) | B-ALL, Ph+ | T-cell acute lymphoblastic leukemia (T-ALL) | Acute myeloid leukemia (AML) |
Anaplastic large cell lymphoma (ALCL) | Chronic myeloid leukemia (CML) | Juvenile myelomonocytic leukemia (JMML) | |
Classical Hodgkin lymphoma (cHL) | Non-Hodgkin lymphoma (NHL) | ||
Pediatric solid tumors | |||
Epithelioid sarcoma | Ewing sarcoma | Hepatoblastoma | Neuroblastoma |
Osteosarcoma | Rhabdomyosarcoma | Wilms tumor |
Transplant and Immune Effector Cells (IECs) | |||
---|---|---|---|
Stem cell mobilization | Allogeneic HSCT | Autologous HSCT | Chimeric antigen receptor T cells (CAR-T) |
Graft versus host disease (GVHD) | Hepatic veno-occlusive disease (VOD/SOS) |
Additional Information
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.
Priorities of this project include:
- Creating a database of all approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology.
- Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
- Creating, maintaining, and disseminating a formalized ontology of anticancer drugs and regimens.
Additional possibilities for this project may include:
- Creating synopses of pivotal clinical trials and regimens
- Prioritizing regimens by their efficacy and/or toxicity
- Capturing historical regimens that were standard-of-care prior to 2005
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.